Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01FQR
|
||||
| Former ID |
DCL000904
|
||||
| Drug Name |
Ocaperidone
|
||||
| Synonyms |
Ocaperidona; Ocaperidonum; Ocaperidona [INN-Spanish]; Ocaperidone (USAN); Ocaperidonum [INN-Latin]; 3-(2-(4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidino)ethyl)-2,9-dimethyl-4H-pyrido(1,2-a)pyrimidin-4-one; 3-[2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl]-2,9-dimethylpyrido[1,2-a]pyrimidin-4-one; 8-[2-[4-(6-fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl]-2,9-dimethyl-6,10-diazabicyclo[4.4.0]deca-2,4,8,10-tetraen-7-one
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Johnson & Johnson
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C24H25FN4O2
|
||||
| InChI |
InChI=1S/C24H25FN4O2/c1-15-4-3-10-29-23(15)26-16(2)19(24(29)30)9-13-28-11-7-17(8-12-28)22-20-6-5-18(25)14-21(20)31-27-22/h3-6,10,14,17H,7-9,11-13H2,1-2H3
|
||||
| InChIKey |
ZZQNEJILGNNOEP-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 129029-23-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 2A receptor | Target Info | Modulator | [526792] | |
| D(2) dopamine receptor | Target Info | Modulator | [526792] | ||
| PANTHER Pathway | 5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | ||||
| Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
| SIDS Susceptibility Pathways | |||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP666:Hypothetical Network for Drug Addiction | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| Ref 467839 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 46). | ||||
| Ref 526792 | Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598). J Pharmacol Exp Ther. 1992 Jan;260(1):146-59. | ||||
| Ref 536463 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. Epub 2007 Jul 31. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.